AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03335293
Drug: 200 mcg Epinephrine
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
Trial: NCT03417193
Drug: opioid free Anesthesia vs Opioid based Anesthesia
RxNorm normalized name: ABT-925 anhydrous free base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
Trial: NCT01561508
Drug: gamma-amino-butyric acid
RxNorm normalized name: gamma-Amino-beta-(p-chlorophenyl)butyric acid
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
Trial: NCT03884452
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets taken orally once daily in the morning or evening
Trial: NCT00987389
Drug: Glucocorticoids [Standard Dose]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
Trial: NCT00987389
Drug: Glucocorticoids [Reduced Dose]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
Trial: NCT01682863
Drug: QAB149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
Trial: NCT01682863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To mimic QAB149
Trial: NCT03127644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension administered orally placebo three times daily for 48 hours.
Trial: NCT01617694
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00134693
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04126213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
Trial: NCT00009009
Drug: immunosuppressive regimen designed to complement HAART
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03003949
Drug: Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release
RxNorm normalized name: Estradiol Patch, 0.1 mg/24 hours weekly transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
Trial: NCT03003949
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
Trial: NCT02987101
Drug: Adipose-Derived Regenerative Cells
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
Trial: NCT01379001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM or PO placebo
Trial: NCT02400242
Drug: ACY-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
Trial: NCT00399256
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02092896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Trial: NCT02092896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
Trial: NCT00663767
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1, dose 2
Trial: NCT00663767
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1
Trial: NCT00663767
Drug: ARRY-371797, p38 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1: multiple dose levels
Trial: NCT00663767
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 2
Trial: NCT00985712
Drug: Huminsulin Regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
Trial: NCT04209205
Drug: AIN457 6 mg/kg i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIN457 6 mg/kg delivered by i.v. infusion
Trial: NCT04209205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AIN457 i.v. infusion
Trial: NCT04209205
Drug: AIN457 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIN457 3 mg/kg delivered by i.v. infusion
Trial: NCT02415569
Drug: Standard Bowel Prep (2L PEG-ELP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
Trial: NCT01620099
Drug: Extrafine treatment (Clenilexx(R) or Foster(R))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
Trial: NCT03915067
Drug: BOTOX® purified neurotoxin complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOTOX® superficial intramuscular injections.
Trial: NCT03343613
Drug: LY3381916
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDO-1 inhibitor administered orally
Trial: NCT03343613
Drug: LY3300054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-L1 inhibitor administered IV
Trial: NCT03915067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections.
Trial: NCT01033942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Trial: NCT04254939
Drug: CS3007 (BLU-285)
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days.
Trial: NCT04158700
Drug: LY3200882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3200882 administered orally
Trial: NCT02362984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
Trial: NCT02362984
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
Trial: NCT00239655
Drug: MK0812
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01943721
Drug: VISION5 Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00406042
Drug: prednisolone acetate 1%
RxNorm normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01882075
Drug: Open loop
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02683265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01102374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo monthly
Trial: NCT01469702
Drug: prednison and azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
Trial: NCT01469702
Drug: prednison, azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
Trial: NCT01469702
Drug: prednison, Azenil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
Trial: NCT00523965
Drug: Liposomal Amphotericin B and Paromomycin Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
Trial: NCT00523965
Drug: miltefosine + Paromomycin sulfate
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
Trial: NCT00818129
Drug: AZD7295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
Trial: NCT00818129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple ascending dose (tbd based on single dose results), oral solution
Trial: NCT02584400
Drug: Injection with the hypoxia tracer [18F]HX4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
Trial: NCT01302613
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
Trial: NCT01302613
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
Trial: NCT01666197
Drug: diclofenac potassium 25 mg tablet
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac potassium 25 mg tablet
Trial: NCT01666197
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02593682
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02512926
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01383135
Drug: F18-FPPRGD2
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
Trial: NCT02143635
Drug: HDM201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02143635
Drug: ancillary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01536158
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
Trial: NCT01536158
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Trial: NCT03757351
Drug: DNL747
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating oral dose
Trial: NCT03757351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating oral dose
Trial: NCT00437632
Drug: GSK598809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
Trial: NCT00437632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo capsules to GSK598809 orally with water.
Trial: NCT00437632
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
Trial: NCT00463242
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03205891
Drug: TAK228
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
Trial: NCT00415194
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
Trial: NCT01297465
Drug: Pergoveris®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
Trial: NCT01297465
Drug: Pergoveris®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
Trial: NCT00150891
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02397408
Drug: Carbon C 11 Choline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV) prior to imaging
Trial: NCT02397408
Drug: Fluorine F 18 Choline
RxNorm normalized name: Fluorine F-18
DrugBank: Fluorine F-18 (DB13134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV) prior to imaging
Trial: NCT02693418
Drug: Acidform 5 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of 5 g vaginally administered Acidform on pH over 7 days
Trial: NCT02693418
Drug: Placebo 4 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
Trial: NCT02693418
Drug: Acidform 4 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of 4 g vaginally administered Acidform on pH over 7 days
Trial: NCT04662138
Drug: directly acting antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
Trial: NCT04049617
Drug: Evixapodlin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally.
Trial: NCT02693418
Drug: Acidform 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of 3 g vaginally administered Acidform on pH over 7 days
Trial: NCT01549106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
Trial: NCT03596892
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT03397771
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo medication provided in a dose titration manner
Trial: NCT00316004
Drug: 7.5% Hypertonic Saline (HS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Trial: NCT00316004
Drug: 0.9% Normal Saline (NS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Trial: NCT00049829
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00614393
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00140426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
Trial: NCT01760525
Drug: CGM097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with CGM097
Trial: NCT02323516
Drug: Acetylsalicylic acid + loperamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
Trial: NCT03527381
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
Trial: NCT02325518
Drug: Subject's habitual PGA monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00103818
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 3 months
Trial: NCT02740699
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 20-40 mg once daily
Trial: NCT03512860
Drug: E4/DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT01877746
Drug: Combination of prednisone and azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
Trial: NCT01877746
Drug: Combination of prednisone and azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
Trial: NCT03560986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glass vials with matching placebo.
Trial: NCT02554136
Drug: HGP0918
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02554136
Drug: HGP0816
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02554136
Drug: HGP0918 + HGP0816
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02958982
Drug: RP3128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
Trial: NCT02958982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
Trial: NCT00437840
Drug: GSK598809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.